Weekly Digest – October 2025 Weekly Digest – October 2025 12 October 2025: Sacituzumab tirumotecan (Sac-TMT) approved for marketing for third indication by the National Medical Products Administration in EGFRm NSCLC following progresssion on EGFR-TKI therapy Sichuan Kelun-Biotech announced that its […]
Weekly Digest – October 2025 Weekly Digest – October 2025 13 October 2025: TQB2102 HER2 bispecific ADC included in the Breakthrough Therapeutic Designation process TQB2102, a HER2 bispecific antibody-drug conjugate (ADC) developed by Sino Biopharmaceutical, has been granted Breakthrough Therapeutic Designation (BTD) by China’s CDE for […]
Weekly Digest – October 2025 Weekly Digest – October 2025 13 October 2025: Mabwell’s CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA Mabwell’s CDH17-targeting ADC, 7MW4911, received IND clearance from China’s NMPA to begin clinical trials in patients with advanced solid […]
Weekly Digest – October 2025 Weekly Digest – October 2025 14 October 2025: DualityBio DB-1324 project received clinical trial approval from HREC and TGA in Australia DualityBio announced that its DB-1324, a next-generation ADC developed using its Duality Immune Toxin Antibody […]
Weekly Digest – October 2025 Weekly Digest – October 2025 15 October 2025: Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio Boehringer Ingelheim and AimedBio have entered a global collaboration and licensing agreement to co-develop a novel antibody-drug conjugate […]
Weekly Digest – October 2025 Weekly Digest – October 2025 17 October 2025: Hansoh Pharma grants Roche an exclusive license to novel CDH17-targeting ADC HS-20110 Hansoh Pharma has granted Roche an exclusive worldwide license (excluding Mainland China, Hong Kong, Macau, and Taiwan) to its investigational CDH17-targeting […]
